Previous longitudinal investigations involving patients with a known mutation are limited but show a similar range of global volumetric changes, suggesting MAPT mutations are associated with a mean annual rate of ∼ 1.6%, intermediate between those with GRN mutations, who exhibit the fastest rate of loss at ∼ 3.5% and C9orf72 whose volumetric rates have been reported as the lowest at ∼ 1.4% and more in line with people with AD (Gordon et al., 2010, Rohrer et al., 2010a, Whitwell et al., 2015a, Whitwell et al., 2011). Here, MAPT is linked to Alzheimer disease.